<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086267</url>
  </required_header>
  <id_info>
    <org_study_id>CA206-001</org_study_id>
    <secondary_id>2010-018944-15</secondary_id>
    <nct_id>NCT01086267</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase 1/2 Study of BMS-908662 (XL281) Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in
      combination with cetuximab; and then to evaluate the tumor response to BMS-908662 when
      administered alone or in combination with cetuximab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1: Single Arm Study

      Phase 2: Randomized Controlled, Parallel
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity will be evaluated according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3</measure>
    <time_frame>Assessments every 1-2 weeks while receiving study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as determined by estimates of objective response rates and response duration</measure>
    <time_frame>Efficacy measured at least every 8 weeks while receiving study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) will be assessed by evaluating markers of RAS/RAF pathway activity</measure>
    <time_frame>PD assessed during the first 4 weeks on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) for BMS-908662 as determined by minimum observed concentrations [Cmin].</measure>
    <time_frame>PK measured during first 4 weeks on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) for BMS-908662 as determined by maximum observed concentrations [Cmax].</measure>
    <time_frame>PK measured during first 4 weeks on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) for BMS-908662 as determined by time of maximum observed concentration [Tmax].</measure>
    <time_frame>PK measured during first 4 weeks on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) for BMS-908662 as determined by area under the concentration-curve for one dosing interval [AUC(TAU)].</measure>
    <time_frame>PK measured during first 4 weeks on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) for BMS-908662 as determined by accumulation index [AI].</measure>
    <time_frame>PK measured during first 4 weeks on study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>BMS-908662 (A1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab (A1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-908662 (B1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-908662 + Cetuximab (B2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-908662</intervention_name>
    <description>Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously</description>
    <arm_group_label>BMS-908662 (A1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-908662</intervention_name>
    <description>Capsules, Oral, (TBD) mg, Q 12 h, Continuously</description>
    <arm_group_label>BMS-908662 (B1)</arm_group_label>
    <arm_group_label>BMS-908662 + Cetuximab (B2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously</description>
    <arm_group_label>Cetuximab (A1)</arm_group_label>
    <arm_group_label>BMS-908662 + Cetuximab (B2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with K-RAS (codon 12 or 13) or B -RAF (V600E) mutation positive advanced or
             metastatic colorectal cancer who have relapsed or are refractory to 2 or more standard
             systemic anticancer regimes for metastatic disease, or are intolerant to existing
             therapies.

          -  Histologic or cytologic confirmation of the diagnosis.

          -  Eastern Cooperative Oncology Group (ECOG) ≤ 1

          -  Adequate organ &amp; marrow function.

        Exclusion Criteria:

          -  Uncontrolled or significant cardiovascular disease.

          -  Phase 2: Prior therapy with a RAF inhibitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Research Associates D/B/A</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Usc Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <disposition_first_submitted>September 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 12, 2015</disposition_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

